The price gap between Memantine products is more than 2.5x

The highest price is 845 won, the lowest price is 334 won

Price of Donepezil is 4x difference between products

Original for Memantine HCl

The price difference between Memantine producst was more than 2.5 times.

 

This is because if there are more than 20 generics depending on the price calculation formula, new products are listed at 85% of the lowest price.

 

Memantine preparations have originally had a large price gap between products, but the gap is widening according to this price calculation formula.

 

According to the industry on the 6th, Ibixa (Memantine HCl) of I-World Pharmaceutical was listed at 334 won on the 1st, which is 85% of the lowest price of the listed same product, as more than 20 products are listed.

 

Before Ibixa's registration, 64 Memantine HCl 10mg preparations were registered, and the lowest price was 393 won for Dongkook Pharmaceutical's Mmentine 10mg.

 

Accordingly, Ibixa was registered at 334, which is 85% of 393 won.

 

Since there are more than 20 generics, the drug price will fall again to 85% of the lowest price if the next product is listed.

 

With the registration of Ibixa, the gap between the highest and lowest prices of Memantine products is more than 2.5 times.

 

The highest price is 845 won.

 

The original for Memantine, Ebixa, costs 803 won.

 

In particular, the price difference between the same drugs is widening in dementia treatments.

 

Donepezil tablet 5mg has quadrupled the price difference between the same drugs.

 

It is analyzed that this is due to the specificity of the dementia treatment market.

 

This is because the market size is large and competition is fierce, but it is not easy to enter customers.

 

Regardless of the price difference, this market has high confidence in patients and medical staff for the original.

 

In addition, because the prescription rate of nursing hospitals that are difficult to access (CSO) is high, the lowest-priced products targeting this are also emerging.

 

An official from the pharmaceutical industry said, "The price strategy of dementia treatments takes into account the specificity of Rx." He explained, "In the case of low-priced drugs, there are preferred medical staff because they are not burdensome to use with other drugs, and it seems that they were aiming for the demand to purchase high-priced drugs at low prices and receive incentives." Analysts say that the price difference does not have a significant impact on patients because patient copy of dementia patients is small.

 

However, the industry reports that such a price difference occurs because the preferences of doctors are different.